F-1/A: Gelteq Limited Eyes Nasdaq Listing with $6.5 Million IPO

Gelteq Limited, an Australian company focused on gel-based delivery solutions, is seeking to raise capital through a U.S. IPO to advance its technology and expand its market reach.

Summary

• Gelteq Limited is planning an initial public offering in the United States, offering 1,300,000 ordinary shares at a price of $5.00 per share.
• The company is focused on developing and commercializing white label gel-based delivery solutions for various products.
• Gelteq's product suite includes edible gels for pets, sports, pharmaceuticals, over-the-counter products, and nutraceuticals.
• The company intends to use the IPO proceeds to advance intellectual property, accelerate sales and marketing, fund research and development, and for general corporate purposes.
• Gelteq has a history of operating losses and expects to incur further losses in the near future.
• The company has received orders for its products, including 265,000 units shipped in the year ended June 30, 2022, and 60,000 units delivered in December 2022.
• Gelteq is pursuing patents for its gel delivery technology and aims to obtain FDA approval for its gel-based drug dosage forms.
• The company faces risks related to market acceptance, competition, intellectual property protection, and regulatory compliance.
• Gelteq is an emerging growth company and a foreign private issuer, which allows it to comply with certain reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth strategies and has secured patents, it also faces financial challenges, including a history of losses and reliance on future capital raises. The document also contains a going concern warning.

Positives

• Gelteq has a diversified product suite across multiple verticals, including pet care, sports, pharmaceuticals, OTC, and nutraceuticals.
• The company has a granted U.S. patent and pending patent applications in several countries, protecting its gel delivery technology.
• Gelteq has established partnerships with companies and academic institutions, such as Monash University, for research and development.
• The company is targeting markets with high demand for differentiated delivery platforms, such as dysphagia and taste-masking.
• Gelteq is pursuing the 505(b)(2) pathway for FDA approval, which can be a faster and less expensive route than traditional drug development.
• The company has strategies in place to mitigate supply chain delays, including establishing an additional R&D facility and a dedicated production line.
• Gelteq has received non-refundable deposits for new product orders, indicating customer interest and commitment.

Negatives

• Gelteq has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• The company faces competition from other companies in the nutraceutical, drug, and supplement delivery markets.
• Gelteq relies on third parties for manufacturing and marketing, which could impact its ability to provide products in a timely and cost-effective manner.
• The company's success depends on market acceptance of its products, which is uncertain given the new and rapidly evolving nature of the gel industry.
• Gelteq's operating results may fluctuate due to factors outside of its control, such as raw material costs and manufacturing expenses.
• There is substantial doubt about Gelteq's ability to continue as a going concern, as indicated in the auditor's report.
• The company is exposed to risks related to the COVID-19 pandemic and the Russian invasion of Ukraine, which could adversely affect its operations and financial results.

Risks

• The market for Gelteq's gels may not develop or become sustainable, which could affect the company's revenues and financial condition.
• The loss of key personnel, such as Mr. Simon H. Szewach and Mr. Nathan J. Givoni, could negatively affect the company's business.
• Clinical testing of Gelteq's products may not lead to successful products or regulatory approval.
• The company relies on third parties to manufacture and market its products, which could adversely impact its revenues and profit margins.
• Gelteq may be unable to adequately control the costs associated with its operations.
• The company could be subject to changes in tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities.
• Acquisitions, joint ventures, and divestitures could result in operating difficulties and other consequences that may harm the company's business.
• The company faces risks related to doing business in the PRC, including changes in economic, political, and social conditions.
• Gelteq may not be able to prevent others from unauthorized use of its intellectual property in the PRC.
• The company may become involved in an intellectual property dispute that could subject it to significant liability.
• Information technology system failures or breaches of Gelteq's network security could interrupt its operations and adversely affect its business.
• Failure to comply with anticorruption and anti-money laundering laws could subject Gelteq to penalties and other adverse consequences.
• The company could be adversely impacted if it fails to comply with U.S. and international import and export laws.
• Gelteq has a substantial amount of intangible assets, and it may be required to write down the value of its intangible assets due to impairment.
• The company will incur costs and be subject to various obligations as a result of being a public company in the United States.
• Any future or current litigation could have a material adverse impact on Gelteq's results of operations, financial condition, and liquidity.
• Australian tax rules may adversely impact Gelteq's results of operations and financial position.
• Gelteq's management team and board control a significant percentage of its Ordinary Shares.
• The company is incorporated in Australia, and its shareholders may have greater difficulty in protecting their interests than they would as shareholders of a corporation incorporated in the United States.
• U.S. investors may have difficulty enforcing civil liabilities against Gelteq, its directors or members of senior management, and the experts named in this prospectus.
• As a foreign private issuer, Gelteq is exempt from a number of rules under the U.S. securities laws and is permitted to file less information with the SEC than a U.S. company.
• As a foreign private issuer, Gelteq is permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards.
• Gelteq may lose its foreign private issuer status in the future, which could result in significant additional cost and expense.
• The company is an emerging growth company under the JOBS Act and will be able to avail itself of reduced disclosure requirements applicable to emerging growth companies, which could make the Ordinary Shares less attractive to investors.
• If Gelteq fails to develop or maintain an effective system of disclosure controls and internal control over financial reporting in compliance with the requirements that will be applicable to it as a public company in the United States, its ability to produce timely and accurate consolidated financial statements or comply with applicable regulations could be impaired and its listing on Nasdaq Capital Market could be terminated.
• Gelteq has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• If Gelteq is a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.
• If a United States person is treated as owning at least 10% of the Ordinary Shares, such holder may be subject to adverse U.S. federal income tax consequences.
• Gelteq's failure to meet the continued listing requirements of Nasdaq could result in a delisting of the Ordinary Shares.
• Because there is no existing market for Gelteq's Ordinary Shares, its initial public offering price may not be indicative of the market price of its Ordinary Shares after this offering, an active trading market in its Ordinary Shares may not develop or be sustained and the market price of its Ordinary Shares could fluctuate significantly, and you could lose all or part of your investment.
• The market price of Gelteq's Ordinary Shares could be adversely affected by future sales, including sales by the selling shareholders pursuant to the Resale Prospectus filed contemporaneously herewith and distributions of its Ordinary Shares or the perception that such sales, including sales by the selling shareholders pursuant to the Resale Prospectus filed contemporaneously herewith, and distributions may occur.
• Gelteq may issue additional Ordinary Shares in the future, which may dilute its existing shareholders. It may also issue securities that have rights and privileges that are more favorable than the rights and privileges accorded to its existing shareholders.
• Certain recent initial public offerings of companies with relatively small public floats comparable to Gelteq's anticipated public float have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. Gelteq's Ordinary Shares may potentially experience rapid and substantial price volatility, which may make it difficult for prospective investors to assess the value of its Ordinary Shares.
• The offering price of the primary offering and resale offering could differ.
• The resale of Ordinary Shares by the Selling Shareholders may cause the market price of Gelteq's Ordinary Shares to decline.
• Gelteq is not likely to issue dividends for the foreseeable future.
• Gelteq expects that any dividend payments on its Ordinary Shares would be declared in U.S. Dollars, and any shareholder whose principal currency is not the U.S. Dollar would be subject to exchange rate fluctuations.
• Gelteq's pre-IPO shareholders will be able to sell their shares after the completion of this offering subject to restrictions under Rule 144 under the Securities Act, which could impact the trading price of its Ordinary Shares.

Future Outlook

Gelteq intends to maximize the commercial potential of its animal health and nutraceutical products through licensing and partnerships, obtain FDA approval for its own gel-based drug dosage forms, expand its product suite, and complete clinical testing of its gel delivery technology with a variety of APIs.

Industry Context

The announcement relates to the pharmaceutical, nutraceutical, and pet care industries, where innovative drug delivery systems are gaining traction. The company's focus on gel-based delivery solutions aligns with the trend towards patient-centric and convenient dosage forms.

Comparison to Industry Standards

• Gelteq is developing ingestible gel technology for nutraceutical, drug, and supplement delivery.
• Comparable companies include Oramed Pharmaceuticals, IntelGenx Technologies Corp., BioDelivery Sciences International Inc., Lexaria Bioscience Corp., Taro Pharmaceuticals Industries Ltd., Catalent Inc., Insulet Corporation, Nutriband Inc., Virpax Pharmaceuticals Inc. and Hempfusion Wellness Inc.
• Gelteq is seeking to position itself as an emerging market leader in dosage forms that utilize ingestible gel technology for nutraceutical, pet care, and pharma.
• Gelteq is promoting its products as superior to other methods of oral delivery (i.e., pills, tablets, gummies).
• Gelteq is highlighting its products as addressing unmet issues around swallowing, taste, dosage and efficacy.
• Gelteq is creating manufacturing and distribution and sale channels permits expedited time-to-market for high-demand products.

Management Changes

Related Party Transactions

• For the year ended June 30, 2022, approximately 50.2% of the orders ordered were with related parties and 91% of revenue recognized were with related parties.
• Cumulatively, from our inception through June 30, 2023, approximately 24% of total units ordered were from related parties and none of the January 2023 or October 2023 orders were from related parties.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares.
• Employees: Potential for growth and development with the expansion of the company.
• Customers: Access to innovative gel-based delivery solutions for various products.
• Suppliers: Opportunities for increased business with Gelteq as it expands its manufacturing and distribution channels.
• Creditors: Increased financial stability and ability to meet obligations with the proceeds from the IPO.

Next Steps

• The company expects to manufacture and deliver the January 2023 orders in the third quarter of the fiscal year ended June 30, 2024.
• The company expects to manufacture and deliver the October 2023 orders in the third quarter of the fiscal year ended June 30, 2024.
• The Company expects to finalize a dedicated production line with a GMP certified manufacturer in Melbourne, Australia in the fourth quarter of the fiscal year ended June 30, 2024 to further enhance production capacity which will avoid future delays.
• The company expects to file its sixth and seventh patent families in the fourth quarter of the fiscal year ended June 30, 2024 to further protect the varying APIs that its gel delivery platform can hold.
• The company anticipates lodging additional patent applications in addition to its sixth and seventh patent families during the financial year ending June 30, 2024, as it further increases its intellectual property portfolio as it continues to attain U.S. Food and Drug Administration (FDA) approvals for its gel-based drug dosage forms through the 505(b)(2) pathway.
• The company expects to begin formal palatability studies for canine products in the third quarter of the fiscal year ended June 30, 2024.

Key Dates

Keywords

Gelteq, IPO, gel-based delivery, pharmaceutical, nutraceutical, pet care, emerging growth company, foreign private issuer, intellectual property, FDA approval